États-Unis · Bourse & Finance · Morningstar

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Publié par Morningstar · États-Unis il y a 16 h

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss In the MEERKAT and SANDCAT studies, vamikibart…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

À lire aussi

Microsoft’s Satya Nadella says AI models need an ‘emergency brake’

Satya Nadella says a company's relationship with AI should have trust issues

Pemex Needs Nearly $110 Billion to Hit Mexico's Output Targets

Microsoft's Nadella says AI needs an ‘emergency brake’ that humans control

SA Asks: Is now the time to buy quantum stocks? If so, which ones?

Ship captains and crews transiting the Strait of Hormuz make so much danger pay that they’re ‘almost being viewed as mercenaries’

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Partager

À lire aussi

Microsoft’s Satya Nadella says AI models need an ‘emergency brake’

Satya Nadella says a company's relationship with AI should have trust issues

Pemex Needs Nearly $110 Billion to Hit Mexico's Output Targets

Microsoft's Nadella says AI needs an ‘emergency brake’ that humans control

SA Asks: Is now the time to buy quantum stocks? If so, which ones?

Ship captains and crews transiting the Strait of Hormuz make so much danger pay that they’re ‘almost being viewed as mercenaries’